Chadé Severin

Chadé Severin represents private and public companies on a wide range of corporate and securities law matters, including mergers and acquisitions, securities law compliance and other general corporate matters.

Ms. Severin’s representations include:

• Juno Therapeutics in its $9 billion acquisition by Celgene;

• Ultragenyx in its successful topping bid for Dimension Therapeutics;
• Gilead in its $11.9 billion acquisition of Kite Pharma;
• Merrimack Pharmaceuticals in its asset sale to Ipsen S.A. for up to $1.025 billion;
• Tobira Therapeutics in its acquisition by Allergan for up to $1.7 billion; and
• Qlik Technologies in its $3 billion acquisition by Thoma Bravo.